News_AntibodySystem

Home / Information / News

Information

Information Close

News

19
2026-08

South Sudan's Cholera Outbreak: What Makes Some Vibrio cholerae Strains Virulent?

South Sudan's 2026 cholera outbreak: 110,574 cases, 1,721 deaths. Explore the molecular basis of Vibrio cholerae virulence—serogroups, TCP, CTXΦ, cholera toxin ctxB, and more. AntibodySystem offers antibodies and proteins for cholera research

More
12
2026-08

AntibodySystem New Citations in July 2026

In July 2026, AntibodySystem products were cited in high-impact journals including iMeta, Science Advances, and npj Biofilms. This summary highlights 7 representative studies covering recurrent pregnancy loss, antithrombotic therapy, allergic inflammation, macrophage-based liver therapy, diabetic vascular complications, EV detection, and influenza immune evasion, showcasing the versatility of AntibodySystem reagents.

More
07
2026-08

Chandipura Virus (CHPV): Structure, Pathogenesis, and Therapeutic Landscape

A 2026 Chandipura virus (CHPV) outbreak in Gujarat, India, reported 184 suspected cases and 22 deaths, all in children under 15. This article reviews CHPV protein architecture (N/P/M/G/L), transmission, neuropathogenic mechanisms, diagnostics, and vaccine development. AntibodySystem offers recombinant proteins and antibodies for CHPV research.

More
06
2026-08

Eli Lilly's Tirzepatide Posts $27.7 Billion in First-Half 2026 Sales: How Dual GIPR/GLP-1R Agonism Outperforms Selective GLP-1R Agonism

Eli Lilly's tirzepatide generated $27.7B in H1 2026, outpacing semaglutide by over $10B. Its imbalanced receptor engagement and biased signaling drive superior glycemic and weight-loss efficacy. AntibodySystem offers antibodies, ELISA kits, and recombinant proteins for tirzepatide and semaglutide research.

More
05
2026-08

Ebola Outbreak: Moderna Begins First Human Trial of Bundibugyo Vaccine——Related Research Tools from AntibodySystem

Moderna initiates first-in-human Phase 1 trial of mRNA-1469 for Bundibugyo Ebola strain amid DRC outbreak. Learn about dsRNA quality control in mRNA vaccines and explore research reagents including anti-dsRNA antibodies and Ebola virus proteins from AntibodySystem.

More
03
2026-08

Antibiotic Antibodies Research Reagents

AntibodySystem offers a panel of high-quality monoclonal antibodies and nanobodies targeting key antibiotics — Amoxicillin (AX), Ampicillin, and Aztreonam (AZT). These reagents are ideal for developing immunoassays (ELISA, LFIA) and biosensors for rapid antibiotic residue detection.

More
29
2026-07

Adeno-Associated Virus (AAV) Research Reagents

Explore AntibodySystem's comprehensive AAV research reagents portfolio — recombinant capsid proteins, monoclonal/polyclonal antibodies, and ELISA kits for AAV1-AAV9, DJ, and rh.1. Validated for ELISA, WB, IF. Accelerate your gene therapy research.

More
28
2026-07

Science Investigation: Why Has an Undisclosed AAV Gene Therapy Case Drawn Global Attention?

A Science investigation has renewed discussions on AAV gene therapy safety, clinical transparency, and vector evaluation. Learn why comprehensive safety assessment is becoming increasingly important and explore research tools supporting AAV vector characterization and gene therapy development.

More
20
2026-07

AntibodySystem DNA/RNA Research Antibodies for Exploring Hidden Nucleic Acid Structures

AntibodySystem provides structure-specific antibodies for R-loops (S9.6), G-quadruplexes (BG4), Z-DNA/Z-RNA (Z22), dsRNA, dsDNA, ssDNA, and ssRNA. Support DRIP-seq, ChIP, IF, ELISA, and viral research. Reliable tools for nucleic acid structure and genome regulation studies.

More
16
2026-07

AAIC 2026: Donanemab, Lecanemab, and Tau-Targeted Therapies Drive Alzheimer’s Disease Research Toward a Multi-Target Era

AAIC 2026 highlights Donanemab long-term data, Lecanemab subcutaneous autoinjector, and Tau-targeted ASO and antibody therapies. Alzheimer’s research moves beyond Aβ toward combined Aβ+Tau multi-target strategies.

More
14
2026-07

AntibodySystem New Citations in June 2026

In June 2026, AntibodySystem products continued to support cutting-edge research across immunology, infectious diseases, oncology, regenerative medicine, and cardiovascular biology. Studies citing AntibodySystem reagents were published in leading journals including MedComm, iScience, and Technology in Cancer Research & Treatment and more, highlighting their applications in therapeutic antibody discovery, targeted anticoagulant development, cancer biomarker validation, and more.

More
09
2026-07

Australia Faces Dual Public Health Challenges: Rising Diphtheria Cases and the First Border Detection of H5N1 Avian Influenza

Australia reports rising diphtheria cases and first border detection of H5N1 HPAI. This article reviews pathogen mechanisms, transmission risks, and surveillance importance, with research reagents for infectious disease studies.

More

Terms of sale Website terms of use Cookie policy Privacy

Copyright © 2025 AntibodySystem SAS. All Rights Reserved. All Products are for Research Use Only